サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1709990

急性間欠性ポルフィリン症の世界市場レポート 2025年

Acute Intermittent Porphyria Global Market Report 2025

出版日
ページ情報
英文 200 Pages
納期
2～10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.28円
急性間欠性ポルフィリン症の世界市場レポート 2025年
出版日: 2025年04月03日
発行: The Business Research Company
ページ情報: 英文 200 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

急性間欠性ポルフィリン症市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR6.3％で59億6,000万米ドルに成長します。予測期間の成長は、急性間欠性ポルフィリン症の罹患率の増加、希少疾患に対する認識の高まり、政府の支援政策、患者擁護の高まり、遺伝子検査サービスの拡大に起因しています。予測期間における主な動向としては、診断技術の進歩、新規治療法の開発、研究開発への投資、製薬企業間の提携、治療における技術革新などが挙げられます。

代謝性疾患の有病率の増加は、急性間欠性ポルフィリン症（AIP）市場の成長を促進すると予想されます。代謝異常は、正常な代謝を阻害する体内の異常な化学反応によって引き起こされる疾患です。遺伝的素因、ライフスタイルの選択、環境の影響、意識の高まりや診断などの要因が、これらの疾患の増加に寄与しています。この増加により、製薬業界は急性間欠性ポルフィリン症を含む希少疾患や遺伝性疾患の治療への投資を促しています。例えば、クリーブランド・クリニックが2023年12月に報告したところによると、遺伝性代謝異常症は世界的に出生1,000～2,500人に1人の割合で発症しており、AIPのような標的治療の必要性が高まっていることが浮き彫りになっています。

AIP市場の主要企業は、患者ケアを改善するため、管理用タブレットなどの先進製品の開発に注力しています。これらの錠剤は、AIPに関連する症状や急性発作を管理または予防するために設計されています。2023年10月、インドに本社を置くAlembic Pharmaceuticals Ltd.は、さまざまな用量（10mg、25mg、50mg、100mg、200mg）で入手可能な塩酸クロルプロマジン錠USPの米国食品医薬品局（USFDA）の承認を取得しました。これらの錠剤は、精神病性障害の症状の管理、悪心・嘔吐のコントロール、および急性間欠性ポルフィリン症を含むその他の症状の緩和のために使用されます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

  • 世界急性間欠性ポルフィリン症PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
  • 最終用途産業の分析
  • 世界の急性間欠性ポルフィリン症市場：成長率分析
  • 世界の急性間欠性ポルフィリン症市場の実績：規模と成長, 2019-2024
  • 世界の急性間欠性ポルフィリン症市場の予測：規模と成長, 2024-2029, 2034F
  • 世界急性間欠性ポルフィリン症総アドレス可能市場（TAM）

第6章 市場セグメンテーション

  • 世界の急性間欠性ポルフィリン症市場診断別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 尿検査
  • 血液検査
  • 血清検査
  • DNA検査
  • その他の診断
  • 世界の急性間欠性ポルフィリン症市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 予防的ヘマチン注入
  • ゴナドトロピン放出ホルモン類似体
  • その他の治療法
  • 世界の急性間欠性ポルフィリン症市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 病院と診療所
  • 外来手術センター
  • 研究センター
  • 世界の急性間欠性ポルフィリン症市場尿検査の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 尿中ポルホビリノーゲン（PBG）検査
  • 尿中アミノレブリン酸（ALA）検査
  • 尿色変化検査
  • 世界の急性間欠性ポルフィリン症市場血液検査の種類別の細分化、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 血漿ポルフィリン濃度検査
  • 血中アミノレブリン酸（ALA）検査
  • 全血球数（CBC）検査
  • 世界の急性間欠性ポルフィリン症市場血清検査の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 血清ポルフィリン濃度検査
  • 肝機能検査（LFT）
  • 血清ALAおよびPBG酵素検査
  • 世界の急性間欠性ポルフィリン症市場DNA検査の種類別の細分化、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 遺伝子変異検査
  • 遺伝子配列検査
  • 世界の急性間欠性ポルフィリン症市場その他の診断のサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
  • ポルフィリンの便検査
  • 画像検査（合併症のCT/MRIスキャン）
  • 酵素活性アッセイ

第7章 地域別・国別分析

  • 世界の急性間欠性ポルフィリン症市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 世界の急性間欠性ポルフィリン症市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 急性間欠性ポルフィリン症市場：競合情勢
  • 急性間欠性ポルフィリン症市場：企業プロファイル
    • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
    • Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
    • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
    • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

  • Sanofi SA
  • AstraZeneca Plc
  • Novartis AG
  • GlaxoSmithKline Plc
  • Takeda Pharmaceutical Company Limited
  • Eli Lilly and Company
  • Gilead Sciences Inc.
  • Amgen Inc.
  • Novo Nordisk A/S
  • Regeneron Pharmaceuticals Inc.
  • Daiichi Sankyo Company Limited
  • Vertex Pharmaceuticals Inc.
  • Eisai Co. Ltd.
  • Octapharma AG
  • BioMarin Pharmaceutical Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

  • 急性間欠性ポルフィリン症市場2029：新たな機会を提供する国
  • 急性間欠性ポルフィリン症市場2029：新たな機会を提供するセグメント
  • 急性間欠性ポルフィリン症市場2029：成長戦略
    • 市場動向に基づく戦略
    • 競合の戦略

第36章 付録

目次
Product Code: r31568

Acute intermittent porphyria (AIP) is a rare genetic disorder affecting the production of heme, an essential component of hemoglobin in the blood. It is characterized by intermittent episodes of severe abdominal pain, gastrointestinal issues, and neurological symptoms such as muscle weakness, seizures, and mental disturbances including anxiety, confusion, or hallucinations.

Diagnosing acute intermittent porphyria typically involves urine tests, blood tests, serum tests, DNA tests, and others. Urine tests analyze a sample to detect elevated levels of porphyrins or their precursors, which indicate AIP. Treatment options include prophylactic hematin infusions, gonadotropin-releasing hormone analogues, and others. These diagnostic and treatment approaches are utilized by hospitals, clinics, ambulatory surgical centers, and research centers.

The acute intermittent porphyria market research report is one of a series of new reports from The Business Research Company that provides acute intermittent porphyria market statistics, including acute intermittent porphyria industry global market size, regional shares, competitors with a acute intermittent porphyria market share, detailed acute intermittent porphyria market segments, market trends and opportunities, and any further data you may need to thrive in the acute intermittent porphyria industry. This acute intermittent porphyria market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The acute intermittent porphyria market size has grown strongly in recent years. It will grow from $4.37 $ billion in 2024 to $4.66 $ billion in 2025 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to rising healthcare expenditure, growth in biopharmaceuticals market, rising prevalence of genetic disorders, expansion of telemedicine services, and growing focus on early detection.

The acute intermittent porphyria market size is expected to see strong growth in the next few years. It will grow to $5.96 $ billion in 2029 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to increasing incidence of acute intermittent porphyria, growing awareness of rare diseases, supportive government policies, growing patient advocacy, and expansion of genetic testing services. Major trends in the forecast period include advancements in diagnostic techniques, development of novel therapeutic options, investment in research and development, collaborations between pharma companies, and technological innovations in treatment.

The increasing prevalence of metabolic disorders is expected to drive growth in the acute intermittent porphyria (AIP) market. Metabolic disorders are conditions caused by abnormal chemical reactions in the body that disrupt normal metabolism. Factors such as genetic predispositions, lifestyle choices, environmental influences, and heightened awareness and diagnosis contribute to the rise in these disorders. This increase is prompting the pharmaceutical industry to invest in treatments for rare and genetic conditions, including acute intermittent porphyria. For example, the Cleveland Clinic reported in December 2023 that inherited metabolic disorders affect approximately 1 in 1,000 to 2,500 births globally, highlighting the growing need for targeted treatments like those for AIP.

Leading companies in the AIP market are focusing on developing advanced products, such as management tablets, to improve patient care. These tablets are designed to manage or prevent symptoms and acute attacks associated with AIP. In October 2023, Alembic Pharmaceuticals Ltd., based in India, received US Food & Drug Administration (USFDA) approval for its Chlorpromazine Hydrochloride Tablets USP, available in various doses (10 mg, 25 mg, 50 mg, 100 mg, and 200 mg). These tablets are used to manage symptoms of psychotic disorders, control nausea and vomiting, and provide relief from other conditions, including acute intermittent porphyria.

In April 2024, the American Porphyria Foundation (APF), a US-based non-profit organization, collaborated with Recordati Rare Diseases. This partnership aims to raise awareness about porphyria and enhance public support and understanding of AIP. Recordati Rare Diseases, an Italy-based, involved in the treatment of acute intermittent porphyria.

Major companies operating in the acute intermittent porphyria market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi SA, AstraZeneca Plc, Novartis AG, GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Novo Nordisk A/S, Regeneron Pharmaceuticals Inc., Daiichi Sankyo Company Limited, Vertex Pharmaceuticals Inc., Eisai Co. Ltd., Octapharma AG, BioMarin Pharmaceutical Inc., Swedish Orphan Biovitrum AB, Alnylam Pharmaceuticals Inc., Mylan N.V., Clinuvel Pharmaceuticals Ltd., Recordati Rare Diseases Inc.

North America was the largest region in the acute intermittent porphyria market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acute intermittent porphyria market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the acute intermittent porphyria market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The acute intermittent porphyria market consists of revenues earned by entities by providing services such as genetic testing, clinical consultation, treatment planning and medication management. The market value includes the value of related goods sold by the service provider or included within the service offering. The acute intermittent porphyria market also includes sales of symptom management products, medical devices, nutritional supplements and emergency kits. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Acute Intermittent Porphyria Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on acute intermittent porphyria market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for acute intermittent porphyria ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The acute intermittent porphyria market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Diagnosis: Urine Test; Blood Test; Serum Test; DNA Test; Other Diagnosis
  • 2) By Treatment: Prophylactic Hematin Infusions; Gonadotropin-Releasing Hormone Analogues; Other Treatments
  • 3) By End-Users: Hospitals And Clinics; Ambulatory Surgical Centers; Research Centers
  • Subsegments:
  • 1) By Urine Test: Urine Porphobilinogen (PBG) Test; Urine Aminolevulinic Acid (ALA) Test; Urine Color Change Test
  • 2) By Blood Test: Plasma Porphyrin Levels Test; Blood Aminolevulinic Acid (ALA) Test; Complete Blood Count (CBC) Test
  • 3) By Serum Test: Serum Porphyrin Levels Test; Liver Function Test (LFT); Serum ALA and PBG Enzyme Test
  • 4) By DNA Test: Genetic Mutation Testing; Gene Sequencing Test
  • 5) By Other Diagnosis: Stool Test for Porphyrins; Imaging Tests (CT/MRI Scans for Complications); Enzyme Activity Assays.
  • Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Roche Holding AG; Merck & Co. Inc.; AbbVie Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Acute Intermittent Porphyria Market Characteristics

3. Acute Intermittent Porphyria Market Trends And Strategies

4. Acute Intermittent Porphyria Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Acute Intermittent Porphyria Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Acute Intermittent Porphyria PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Acute Intermittent Porphyria Market Growth Rate Analysis
  • 5.4. Global Acute Intermittent Porphyria Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Acute Intermittent Porphyria Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Acute Intermittent Porphyria Total Addressable Market (TAM)

6. Acute Intermittent Porphyria Market Segmentation

  • 6.1. Global Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Urine Test
  • Blood Test
  • Serum Test
  • DNA Test
  • Other Diagnosis
  • 6.2. Global Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Prophylactic Hematin Infusions
  • Gonadotropin-Releasing Hormone Analogues
  • Other Treatments
  • 6.3. Global Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals and Clinics
  • Ambulatory Surgical Centers
  • Research Centers
  • 6.4. Global Acute Intermittent Porphyria Market, Sub-Segmentation Of Urine Test, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Urine Porphobilinogen (PBG) Test
  • Urine Aminolevulinic Acid (ALA) Test
  • Urine Color Change Test
  • 6.5. Global Acute Intermittent Porphyria Market, Sub-Segmentation Of Blood Test, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Plasma Porphyrin Levels Test
  • Blood Aminolevulinic Acid (ALA) Test
  • Complete Blood Count (CBC) Test
  • 6.6. Global Acute Intermittent Porphyria Market, Sub-Segmentation Of Serum Test, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Serum Porphyrin Levels Test
  • Liver Function Test (LFT)
  • Serum ALA and PBG Enzyme Test
  • 6.7. Global Acute Intermittent Porphyria Market, Sub-Segmentation Of DNA Test, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Genetic Mutation Testing
  • Gene Sequencing Test
  • 6.8. Global Acute Intermittent Porphyria Market, Sub-Segmentation Of Other Diagnosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Stool Test for Porphyrins
  • Imaging Tests (CT/MRI Scans for Complications)
  • Enzyme Activity Assays

7. Acute Intermittent Porphyria Market Regional And Country Analysis

  • 7.1. Global Acute Intermittent Porphyria Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Acute Intermittent Porphyria Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Acute Intermittent Porphyria Market

  • 8.1. Asia-Pacific Acute Intermittent Porphyria Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Acute Intermittent Porphyria Market

  • 9.1. China Acute Intermittent Porphyria Market Overview
  • 9.2. China Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Acute Intermittent Porphyria Market

  • 10.1. India Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Acute Intermittent Porphyria Market

  • 11.1. Japan Acute Intermittent Porphyria Market Overview
  • 11.2. Japan Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Acute Intermittent Porphyria Market

  • 12.1. Australia Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Acute Intermittent Porphyria Market

  • 13.1. Indonesia Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Acute Intermittent Porphyria Market

  • 14.1. South Korea Acute Intermittent Porphyria Market Overview
  • 14.2. South Korea Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Acute Intermittent Porphyria Market

  • 15.1. Western Europe Acute Intermittent Porphyria Market Overview
  • 15.2. Western Europe Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Acute Intermittent Porphyria Market

  • 16.1. UK Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Acute Intermittent Porphyria Market

  • 17.1. Germany Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Acute Intermittent Porphyria Market

  • 18.1. France Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Acute Intermittent Porphyria Market

  • 19.1. Italy Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Acute Intermittent Porphyria Market

  • 20.1. Spain Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Acute Intermittent Porphyria Market

  • 21.1. Eastern Europe Acute Intermittent Porphyria Market Overview
  • 21.2. Eastern Europe Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Acute Intermittent Porphyria Market

  • 22.1. Russia Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Acute Intermittent Porphyria Market

  • 23.1. North America Acute Intermittent Porphyria Market Overview
  • 23.2. North America Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Acute Intermittent Porphyria Market

  • 24.1. USA Acute Intermittent Porphyria Market Overview
  • 24.2. USA Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Acute Intermittent Porphyria Market

  • 25.1. Canada Acute Intermittent Porphyria Market Overview
  • 25.2. Canada Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Acute Intermittent Porphyria Market

  • 26.1. South America Acute Intermittent Porphyria Market Overview
  • 26.2. South America Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Acute Intermittent Porphyria Market

  • 27.1. Brazil Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Acute Intermittent Porphyria Market

  • 28.1. Middle East Acute Intermittent Porphyria Market Overview
  • 28.2. Middle East Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Acute Intermittent Porphyria Market

  • 29.1. Africa Acute Intermittent Porphyria Market Overview
  • 29.2. Africa Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Acute Intermittent Porphyria Market Competitive Landscape And Company Profiles

  • 30.1. Acute Intermittent Porphyria Market Competitive Landscape
  • 30.2. Acute Intermittent Porphyria Market Company Profiles
    • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Acute Intermittent Porphyria Market Other Major And Innovative Companies

  • 31.1. Sanofi SA
  • 31.2. AstraZeneca Plc
  • 31.3. Novartis AG
  • 31.4. GlaxoSmithKline Plc
  • 31.5. Takeda Pharmaceutical Company Limited
  • 31.6. Eli Lilly and Company
  • 31.7. Gilead Sciences Inc.
  • 31.8. Amgen Inc.
  • 31.9. Novo Nordisk A/S
  • 31.10. Regeneron Pharmaceuticals Inc.
  • 31.11. Daiichi Sankyo Company Limited
  • 31.12. Vertex Pharmaceuticals Inc.
  • 31.13. Eisai Co. Ltd.
  • 31.14. Octapharma AG
  • 31.15. BioMarin Pharmaceutical Inc.

32. Global Acute Intermittent Porphyria Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Acute Intermittent Porphyria Market

34. Recent Developments In The Acute Intermittent Porphyria Market

35. Acute Intermittent Porphyria Market High Potential Countries, Segments and Strategies

  • 35.1 Acute Intermittent Porphyria Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Acute Intermittent Porphyria Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Acute Intermittent Porphyria Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer